Table 3. Results.

Study (Period of Recruitment)	Treatment- related Deaths after Randomisation		Postoperative Deaths due to Surgical Complications/Resected	Cancer- related Deaths		Local - Regional Recurrences		Distant Metastases		Number of patients alive at 1 year follow-up		Number of patients alive at 2 years follow-up		Patients per Arm
	Arm 1	Arm 2	Arm 1	Arm 1	Arm 2	Arm 1	Arm 2	Arm 1	Arm 2	Arm 1	Arm 2	Arm 1	Arm 2	Arm 1	Arm 2
RTOG 89-01 (1990-1994)	2	1	2/26	n.g.	n.g.	n.g.	n.g.	n.g.	n.g.	19	21	13	11	29	32
NCI Canada (closed 1995)	0	0	0/13	11	10	8	6	1	4	12	10	7	6	16	15
MRC (1995-1999)	2	0	2/4	16	19	n.g.	n.g.	n.g.	n.g.	13	10	3	3	24	24
EORTC 08941 (1994-2002)	6	1	6/154	n.g.	n.g.	45	80	78	59	104	115	58	66	167	165
NordicTOG (1998-2009)	n.g.	n.g.	n.g./132	n.g.	n.g.	n.g.	n.g.	n.g.	n.g.	107	104	67	60	170	171
INT 0139 (1994-2001)	16	4	15/155	109	136	21	43	98	110	136	131	97	89	202	194
ESPATUE (2004-2012)	5	2	5/70	31	41	n.g.	n.g.	n.g.	n.g.	63	66	51	47	81	80

Arm 1 – induction treatment plus surgery, (2): Arm 2 – conservative treatment: combined chemoradiotherapy without resection,

n. s. – not significant, n.g. - not given, trials using simultaneous chemotherapy within the definitive radiochemotherapy arms are given in italics.